• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>公司动态>2009年Qiagen 已收购DxS Ltd——创造个性化医疗的领导

    2009年Qiagen 已收购DxS Ltd——创造个性化医疗的领导

    QIAGEN2010年1月12日 18:39 点击:2867

    QIAGEN
    (QGEN) 22.37 : Qiagen宣布,已收购DxS Ltd (DxS),後者为未上市公司,制造与开发搭配诊断产品,收购价为9500万美元现金,如果达到预订财测目标,将另外支付3500万美元。

    QIAGEN公司收购DxS有限公司 -创造个性化医疗的领导
    此外,QIAGEN公司推出首次管道及其配套的诊断,该公司认为是在深度?#25512;?#38754;上无与伦比
    芬洛,荷兰,2009年9月22日 - QIAGEN公司内华达州(纳斯达?#26031;善贝?#30721;:QGEN;法兰克福,总理标准:卡塔尔投资局)今天宣布,它已经收购DxS有限公司(DxS),是一家私人控股开发商和总部设在曼彻斯特的同伴诊断产品制造商,英国。此次交?#36164;?#22823;约95美元的现金万美元(符合通常的收购价格调整),加上高达另外3500万美元,如果?#20184;?#30340;商业?#25512;?#20182;里程碑满足。

    通过这次收购,QIAGEN公司采取了在个性化医疗保健(PHC)的新?#36125;?#24378;有力的领导地位。该公司认为,它提供所有必需的元素,以帮助推动?#36864;?#36896;这个迅速崛起的医疗趋势。

    此外,QIAGEN公司公布了第一次合并后的公司目前超过15与制药公司的市场和/或诊断产品开发的合作伙伴积极。该规划涵盖基因,表达,后生?#25512;?#20182;标记。 QIAGEN公司认为,这条管道是最深的个性化医疗的分子诊断等关键领域的投?#39318;?#21512;。

     

    收购DxS

    在DxS收购使QIAGEN公司的分子诊断化验和知识产权组合,以及积极的或计划中的同伴在肿瘤诊断的伙伴关系深厚的渠道与许多领先的制药公司,包括在这一领域最大的制药公司7 。这些资产的补充QIAGEN公司现有的个性化医疗诊断解决方案组合和?#30475;?#24863;到非常QIAGEN公司的样品制备和检测技术的协同作用。

    DxS制定了?#24066;?#20998;子肿瘤学医生预测病人的反应,某些治疗方式,以使癌症治疗更加?#34892;?#21644;安全的诊断化验集。目前正在销售的产品组合涵盖7实时PCR检测,其中包括一个基因突变的地位k - ras基因,这对来自转移性结肠癌(mCRC与表皮生长因子受体抑制剂)患者的治疗成功的指标测试。此外,三个化验是在短期内管道,并进一步分析得到的中期正在酝酿中。 DxS'组合化验,都在其销售和管道,是非常适合与QIAGEN的平台手段,包括QIAsymphony和转子基因问:现有的?#20934;?#20351;用

    DxS是带来了哪些分子伴侣诊断市场的先驱者之一。在TheraScreen:K - ras基因突变?#32422;?#30418;®由DxS开发已经CE的标记。在美国,测试预计将提交监管机构批准,在2010年(物业管理公司)向FDA。据?#20848;疲?#22312;未来的市场整体亩- ras基因测试可能可达1亿美元。 DxS目前的产品组合,短期产品包括10独特和专有化验。公司积累了其现有的和计划的诊断内容的重要的知识产权组合。

    他说:“DxS收购QIAGEN公司的战略是非常重要的交易。它结合了两个领导职务,以创建一个在医疗领域的变革非常?#30475;?#30340;领导者:个性化医疗。这项交?#36164;?#25105;们的战略,带领分子诊断的关键因素,为基础的预防,分析和个性化医疗。这三个因素将大大形状,并有助于今后改进和保健有可能提供巨大利益的病人,以及为纳税人,提供卓越的价值,以及制药业“,说?#21644;?#34892;米沙茨,对QIAGEN公司首席执行官。

    “QIAGEN公司是DxS理想的合作伙伴在全球?#27573;?#20869;推出的化验,以我们的伙伴关系提升到更高层次,并采取了同伴诊断的领导地位”,斯蒂芬说小,DxS的创始人和首席执行官。 “与任何其他公司,我们认为,QIAGEN公司谈到对大型制药和生物技术公司的同伴诊断?#27573;?#26368;广的选择 - 从一个独立的销售开始达到?#26031;?#27867;的技术,研发和制造能力达到了监管事务和获得医生的专业知识创造和实验室。“

    “这样的组合有可能的每个人创造经典双赢”,说同伴沙茨。 “我们相信,QIAGEN公司可利用其增强的战略地位,充分利用机会,在个性化医疗:医药?#31361;?#21487;以从一个更?#30475;螅?#29420;立的和有重点的合作伙伴的利益更好地满足他们特殊的发展需要,员工可以受益于增加就业机会,医生可以受益更快的访问的诊断和治疗,以更好的工具,可以从医疗保健系统的潜在利益为切实?#34892;?#30340;治疗增加。但最重要的是,病人谁?#29616;?#30340;疾病,如癌症,痛苦,从中获益,这些新的趋势显着在个性化医疗,从而导致不必要的,甚至有害的治疗,因此,?#21592;?#20813;在他们的生活质量的提高。“

    DxS的高级管理层将加入该公司在迅速发展的个性化医疗的重点领域,促进对这一关键部门进一步扩大的快速集成和集中领导作用QIAGEN公司。为此,QIAGEN公司打算建立一个在曼彻斯特在制药,携手?#27493;?#21331;越?#34892;腄xS的总部。鉴于高层次的协同作用,QIAGEN公司预计将增长曼彻斯特的位置。

     

    交易亮点

    QIAGEN公司认为它采取了一种个性化的医疗保健分子诊断的领导地位,致力于帮助推动?#36864;?#36896;这个迅速崛起的趋势。
    QIAGEN公司推出首次在其合作伙伴的诊断管线深度和目前正积极的伙伴关系超过15英寸这被认为是在该行业最这种管道之一。
    QIAGEN公司扩大了个性化医疗,在公司战略的一个重要支柱,把重点放在领导的分子诊断为基础的预防,分析,和个性化医疗。
    QIAGEN公司造成了同伴诊断领先的投?#39318;?#21512;:
    DxS增加了7个基因化验目标包括K标志物,RAS和EGFR29,这可能是确定病人的反应,某些癌症治疗有用(如结肠癌,肺癌)。
    QIAGEN公司现有产品已经包括焦磷酸的k - ras基因,携带BRAF和甲基化标志物化验目标,以及基因表达和对未来的标记及仪器平台miRNA的化验发现大批自动完成这些测试。
    吸积调整后每股收益在2010年以后。
    非常协同,避免重叠和无缝集成预期。 DxS'高级管理人员将继续承担在扩大与制药和生物技术在同伴诊断QIAGEN公司的伙伴关系的领先地位。
     

    财务细节

    根据协议条款,QIAGEN公司收购DxS整个发行股本。 QIAGEN公司预计,支付一次性在2009年第三季度的费用大约在每股0.02美元,与此次收购有关。这些费用主要涉及咨询,并与收购和注销而发生的某些资产的咨询费用。此外,根据初步分析,并按照投?#39318;?#21512;的简化,QIAGEN公司预期这一交易将有助于在2009年余下的销售额约为600万美元和30美元左右,在2010年的销售亿美元。经过调整后不包括一次性支出,整合和重组费用,和收购相关的无形资产摊销,收购预计将在中立2009年剩余的EPS和美国将在2010年摊薄$ 0.02。 2010年以后,预计此次收购将增加每股收益调整。杰弗里斯担?#26410;?#27425;交易的?#20848;?#36130;务顾问。

     

    关于QIAGEN公司在分子诊断

    有了一个运行速度超过美国的4.5亿美元的销售额,并在该领域的快速增长,QIAGEN公司认为它是在分子诊断的领导者,包括病毒载量检测和血液检测。

    QIAGEN公司确定了三个领域的实验室为基础的,是专注于分子诊断:

    预防:这部分涵盖在早期疾病或风险的目的,无症状患者的检测和定期检验标志。这些化验是通常由大批量实验室。 QIAGEN公司的投?#39318;?#21512;,HPV检测,此外,在化验的发展小组(包括?#30053;?#20307;和淋病的测试)解决最具吸引力和预防增长最快的细分市场。这些化验就可以执行现行制度和QIAGEN公司QIAensemble平台。该平台预计将于2010年?#33258;諗分?#21644;美国在2012年中推出,并可望在吞吐量和实用性方面,在分子诊断筛查的新标准。
    分析:这部分包括对症状的病人,建立或确认的诊断测试。这些化验大多表现在?#31995;?#30340;流量,但往往是更高的每测试值。 QIAGEN公司的分子(“80病原体)诊断化验组合被认为是世界上最广泛的一个,用于检测和配置病原体。这部分还包括遗传?#25512;?#20182;化验数目。
    个性化医疗保健:QIAGEN公司认为,这是大多数分子诊断领域的变革。这些化验是用来指导治疗前诊断症状的病人。他们是典型的高价值,低量化验。 QIAGEN公司今天出售约20个性化医疗化验。
    在个性化医疗保健和分析吞吐量需求低于在预防部分,但对带宽的要求(样本种类等)要高得多。随机存取,连续负载QIAsymphony平台(样本的结果,其中第一单元已经非常成功地发射)是为这些细分市场设计的。

     

    关于QIAGEN在个性化医疗保健

    QIAGEN公司认为,它带来了特殊的价值主张为伴侣诊断制药公司的发展项目。该公司被认为是一个重要伙伴,因为它是:

    最大的分子诊断公司的收入为基础,技术和产品组合宽度,外验血/病毒载量检测。
    一个重要供应商,医药发现与开发已经今天。
    一个广泛的技术组合所有者分子样品和检测技术。
    独立?#22909;?#26377;一家制药公司所拥有。
    具有强烈的监管存在的公司,销售渠道的实力和全球影响力。
     

    关于伴侣诊断和个性化医疗保健

    同伴诊断预计将成为一个关键因素,实现个性化医疗(PHC)的变革趋势。除了对肝癌的重大利益日益认识到医疗保健的主要参与者(付款人,医生,管理者,病人),在分子诊断新的可能性,特别是最近的监管和付款人的决定,特别是围绕产品在DxS'组合起到了关键作用,加快朝着更为一体化的诊断信息来指导治疗的趋势。

    虽然最新的同伴诊断为“改装”的诊断,即增加了追溯批准的药品,以?#32435;?#32467;果,即诊断,诊断的同伴新一代正在开发的药物一起预测病人群体反应的药物治疗,提高其疗效和安全。通过有关的某些特定基因变异生物标志物检测,保健专业人员可以自定义他们的治疗,避免不必要的或有害的治疗。个性化医疗观念在临床领域,如心血管疾病和神经系统疾病和 - 最显着的 - 癌症治疗的决定,在日益重要的作用。有28个同伴的?#34892;?#22522;因组由美国食品药品管理局确定的?#27573;?#20869;的生物标志物FDA的批准的药品标签的诊断测试。据?#30340;?#20154;士报道,个性化医疗市场每年增长24%,在过去十年中,达13美元,2008年亿美元。

    关于QIAGEN:
    QIAGEN公司内华达州,一家荷兰控股公司,是全球领先的样品制备和检测技术的全球供应商。样品制备技术用于隔离和处理DNA,RNA和蛋白质的生物样品,如血液或组织。检测技术可用于制造这种孤立的生物分子可见。 QIAGEN公司已经开发和市场500多个样品,检测产品,以及自动化解决方案等消耗品。该公司提供其产品的分子诊断实验室,学术研究,制药和生物技术公司,和应用测试用途,如法医,动物或食品检测和制药过程控制?#31361;А?QIAGEN的检测技术包括分子诊断测试的最广泛的一个小组在全球推出。这个小组包括杂交捕获HPV检测,这是一个“黄金标准高的人乳头状瘤病毒(HPV),是宫颈癌的主要成因,以及对传染病的测试解决方案的一整套风险类型测试”视为和同伴诊断。 QIAGEN公司雇用了30多个地点的超过3,200名员工。有关QIAGEN公司的更多信息可在http://www.qiagen.com/。

    关于DxS:
    DxS是一家公司,提供个性化医疗的分子诊断,以帮助他们选择(伴侣诊断)分子配置为病人安全,?#34892;?#30340;治疗医生和制药公司。在曼彻斯特,英国,该公司总部设在两个国家约80名员工,其中大部分在英国。更多关于DxS信息可在http://www.dxsdiagnostics.com/。

    QIAGEN新闻稿
    QIAGEN Acquires DxS Ltd – Creating Leadership in Personalized Healthcare
    In addition, QIAGEN unveils for the first time its companion diagnostic pipeline, which the Company believes is unmatched in terms of depth and profile
    VENLO, The Netherlands, September 22, 2009 - QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom. The transaction is valued at approximately US$ 95 million in cash (subject to customary purchase price adjustments), plus up to an additional US$ 35 million if specified commercial and other milestones are met.

    With this acquisition, QIAGEN has taken a strong leadership position in the new era of personalized healthcare (PHC). The Company believes it offers all the required elements to help drive and shape this rapidly emerging trend in healthcare.

    In addition, QIAGEN unveiled for the first time that the combined company is currently active in over 15 collaborations with pharmaceutical companies to market and / or develop companion diagnostic products. The programs span genetic, expression, epigenetic and other markers. QIAGEN believes that this pipeline is the deepest such portfolio in the pivotal field of molecular diagnostics for personalized healthcare.

     

    Acquisition of DxS

    The acquisition of DxS brings to QIAGEN a portfolio of molecular diagnostic assays and intellectual property, as well as a deep pipeline of active or planned companion diagnostic partnerships in oncology with many of the leading pharmaceutical companies, including seven of the largest drug makers in this field. These assets complement QIAGEN's existing strong portfolio of personalized healthcare diagnostic solutions and are very synergistic with QIAGEN's sample and assay technologies.

    DxS has developed a set of molecular diagnostic assays which allow physicians in oncology to predict patients' responses to certain treatments in order to make cancer therapies more effective and safer. The currently marketed portfolio spans seven real-time PCR tests including a test for the mutation status of the oncogene K-RAS, which is indicative for successful treatment of patients suffering from metastatic colorectal cancer (mCRC) with EGFR inhibitors. In addition, three assays are in the near-term pipeline and further assays are in the medium-term pipeline. DxS' portfolio of assays, both marketed and in its pipeline, is strongly suitable for use with QIAGEN's existing suite of platform instruments, including QIAsymphony and Rotor-Gene Q.

    DxS is one of the pioneers which have brought molecular companion diagnostics to market. The TheraScreen: K-RAS Mutation Kit® developed by DxS has already been CE-marked. In the United States, the test is expected to be submitted to the FDA for regulatory approval (PMA) in 2010. It is estimated that in the future the market for overall K-RAS testing could reach up to US$ 100 million. DxS' current portfolio and near-term pipeline includes ten unique and proprietary assays. The company has accumulated a significant intellectual property portfolio for its current and planned diagnostic content.

    "The acquisition of DxS is strategically a highly important transaction for QIAGEN. It combines two leadership positions to create a very powerful leader in a transformational area of healthcare: personalized healthcare. This transaction is a key element of our strategy to lead in molecular diagnostic-based prevention, profiling and personalized healthcare. These three elements are expected to significantly shape and contribute to future improvements in healthcare and have the potential to provide significant benefits to patients as well as exceptional value for payers, providers, and the pharmaceutical industry", said Peer M. Schatz, CEO of QIAGEN.

    "QIAGEN is the ideal partner for DxS to globally roll out our assays, to take our partnerships to the next level and to take a leadership position in companion diagnostics", said Stephen Little, founder and CEO of DxS. "Unlike any other company, we believe that QIAGEN addresses the broadest range of companion diagnostic options for pharmaceutical and large biotech companies - starting from an independent sales reach over broad technology, R&D and manufacturing capabilities up to expertise in regulatory affairs and access creation to physicians and laboratories."

    "This combination has the potential to create a classical win-win situation for everyone involved", said Peer Schatz. "We believe that QIAGEN can use its enhanced strategic position to leverage the opportunities in personalized healthcare: pharma customers can benefit from a stronger, independent and focused partner to better serve their special development needs, employees can benefit from enhanced career opportunities, physicians can benefit from faster access to better tools for diagnosis and treatment, and healthcare systems can benefit from the potential for increases in effective and efficient treatments. But most importantly, patients who suffer from serious diseases, such as cancer, stand to benefit significantly from these new trends in personalized healthcare, which can lead to the avoidance of unnecessary or even harmful treatments and therefore to an increase in the quality of their lives."

    DxS' senior management will join QIAGEN in leading roles in the Company's rapidly expanding personalized healthcare focus area, facilitating rapid integration and focus on the further expansion of this key segment. For that purpose, QIAGEN intends to establish DxS' headquarters in Manchester as a Center of Excellence in Pharma Partnering. Given the high level of synergies, QIAGEN expects to grow the Manchester location.

     

    Transaction Highlights

    QIAGEN believes it has taken a leadership position in molecular diagnostics for personalized healthcare, positioned to help drive and shape this rapidly emerging trend.
    QIAGEN unveils for the first time the depth of its partnered companion diagnostics pipeline and is now active in over 15 partnerships. This is believed to be one of the deepest such pipelines in the industry.
    QIAGEN expands leadership in personalized healthcare, a key pillar in the Company's strategy to focus on molecular diagnostic-based prevention, profiling, and personalized healthcare.
    QIAGEN creates a leading portfolio in companion diagnostics:
    DxS adds seven PCR assays targeting biomarkers including K-RAS and EGFR29, which may be useful in identifying patients' response to certain cancer treatments (e.g. colon, lung cancer).
    QIAGEN's existing portfolio already included pyrosequencing-based K-RAS, BRAF and methylation assays targeting biomarkers, as well as large numbers of gene expression and miRNA assays for discovery of future biomarkers and instrument platforms to automate these tests.
    Accretion to adjusted EPS beyond the year 2010.
    Very synergistic; minimal overlap and seamless integration expected. DxS' senior management will continue to assume leading positions in expanding QIAGEN's partnerships with pharma and biotech in companion diagnostics.
     

    Financial Details

    Under the terms of the agreement, QIAGEN acquired the entire outstanding share capital in DxS. QIAGEN expects to incur one-time charges of approximately US$ 0.02 in EPS in the third quarter 2009 in connection with this acquisition. These charges primarily relate to consulting and advisory fees incurred in connection with the acquisition and the write-off of certain assets. In addition, based on preliminary analyses and following the streamlining of the portfolio, QIAGEN expects this transaction to contribute approximately US$ 6 million in sales in the remainder of 2009 and approximately US$ 30 million in sales in 2010. On an adjusted basis excluding one-time charges, integration and restructuring costs, and amortization of acquisition related intangible assets, the acquisition is expected to be neutral to EPS in the remainder of 2009 and to be dilutive by US$ 0.02 in 2010. Beyond 2010, it is expected that the acquisition will be accretive to adjusted EPS. Jefferies acted as exclusive financial advisors in this transaction.

     

    About QIAGEN in Molecular Diagnostics

    With a run-rate over US$ 450 million in sales and rapid growth in this segment, QIAGEN believes it is a leader in molecular diagnostics, excluding viral load testing and blood screening.

    QIAGEN has defined three segments in laboratory-based molecular diagnostics it is focusing on:

    Prevention: This segment covers markers tested for in asymptomatic patients for the purpose of early disease or risk detection and in regular intervals. These assays are typically performed by laboratories in high volumes. QIAGEN's portfolio in HPV testing and, in addition, the panel of assays in development (including tests for chlamydia and gonorrhea) address the most attractive and fastest growing segments in Prevention. These assays can be performed on current systems and on QIAGEN's QIAensemble platform. This platform is expected to be launched in late 2010 in Europe and in mid 2012 in the United States and is expected to set a new standard in molecular diagnostic screening in terms of throughput and utility.
    Profiling: This segment covers tests performed on symptomatic patients to create or confirm a diagnosis. The assays are mostly performed at lower throughputs, but are often of higher value per test. QIAGEN's portfolio of molecular diagnostic assays (>80) for pathogens is considered one of the broadest in the world and is used to detect and profile pathogens. This segment also includes a number of genetic and other assays.
    Personalized Healthcare: QIAGEN believes that this is the most transformative area of molecular diagnostics. These assays are used to guide therapy for pre-diagnosed symptomatic patients. They are typically higher value, lower volume assays. QIAGEN today sells approximately 20 assays in personalized healthcare.
    In Personalized Healthcare and Profiling throughput requirements are lower than in the segment of Prevention, but the bandwidth requirements (sample types, etc.) are much higher. The random access, continuous load QIAsymphony platform (sample to result, of which the first modules have been very successfully launched) was designed for these segments.

     

    About QIAGEN in Personalized Healthcare

    QIAGEN believes it brings a special value proposition to pharmaceutical companies for companion diagnostics development projects. The Company is considered a key partner as it is:

    The largest molecular diagnostics company based on revenues, technology and portfolio breadths, outside blood screening/viral load testing.
    A significant supplier to pharmaceutical discovery and development already today.
    Owner of a broad technology portfolio in molecular sample & assay technologies.
    Independent: not owned by a pharmaceutical company.
    A company with strong regulatory presence, sales channel strength and global reach.
     

    About Companion Diagnostics and Personalized Healthcare

    Companion diagnostics are expected to become a key contributor to the transformational trend towards personalized healthcare (PHC). In addition to the increasing awareness of the significant benefits of PHC to key players in healthcare (payers, physicians, regulators, patients), new possibilities in molecular diagnostics and in particular very recent regulatory and payer decisions, most notably around products where DxS' portfolio plays a key role, have accelerated the trend towards a more integrated use of diagnostic information to guide therapy.

    While most current companion diagnostics are "retrofitted" diagnostics, i.e. diagnostics that were retroactively added to approved drugs to improve outcomes, the new generation of companion diagnostics is being developed together with drugs to predict responses of patient populations to the drug treatment and increase its efficacy and safety. By testing for specific genetic variations related to certain biomarkers, health professionals can customize their therapies and avoid unnecessary or harmful treatments. The concept of personalized healthcare plays an increasingly important role in treatment decisions in clinical areas such as cardiovascular and neurological diseases and - most prominently - in cancer. There are 28 companion diagnostic tests for valid genomic biomarkers identified by the FDA in the context of FDA-approved drug labels. According to industry reports, the market for personalized healthcare grew annually at 24% over the last decade, amounting to US$ 13 billion in 2008.

    About QIAGEN:
    QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,200 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

    About DxS:
    DxS is a personalized healthcare company providing molecular diagnostics to aid doctors and drug companies in selecting safe and effective therapies for patients based on their molecular profiles (Companion diagnostics). Headquartered in Manchester, UK, the company employs approximately 80 employees in two countries, most of them in the UK. More information about DxS can be found at http://www.dxsdiagnostics.com/.

    SAFE HARBOR STATEMENT
    Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing, molecular diagnostics, personalized healthcare and companion diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.

     

    (来源: QIAGEN )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载?#20445;?#24517;须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    加入亲友圈 喜乐彩走势分析 民国围棋罐 辽宁11选5预测分析大师 3d彩票软件库 贵州11选5和值走势图 赌徒银行单双中特 快乐三张牌官方下载 大乐透开奖下期预测号码 北京福彩网 双色球预测最准确的 湖南体育彩票幸运赛车走势图 河北20选5奖金多少 七星彩走势图预测下期 十一运夺金任选2